scholarly journals Gender Differences in Medication Use: A Drug Utilization Study Based on Real World Data

2020 ◽  
Vol 17 (11) ◽  
pp. 3926 ◽  
Author(s):  
Valentina Orlando ◽  
Sara Mucherino ◽  
Ilaria Guarino ◽  
Francesca Guerriero ◽  
Ugo Trama ◽  
...  
Keyword(s):  
Gender Differences ◽  
Drug Utilization ◽  
Real World ◽  
Anatomical Therapeutic Chemical ◽  
Treated Patient ◽  
Drug Prescription ◽  
Medication Use ◽  
Administrative Databases ◽  
Drug Utilization Study ◽  
Campania Region

A gender-specific drug utilization study was performed in the Campania region, Southern Italy. Data were based on outpatient drug prescriptions collected from administrative databases. The study population included all patients with at least one drug prescription in 2018. Prevalence was used as a measure to estimate the degree of exposure to drugs. A total of 3,899,360 patients were treated with at least one drug (54.2% females). The number of prescriptions was higher in females than males (55.6% vs. 44.4%). Females recorded higher prevalence for the majority of therapeutic groups (ATC II—anatomical therapeutic chemical), as well as for anti-inflammatory and antirheumatic products drugs (M01) (25.6% vs. 18.7%, risk ratio (RR): 0.73), beta blocking agents (C07) (14.5% vs. 11.6%, RR: 0.80), psychoanaleptics (N06) (7.1% vs. 3.7%, RR: 0.52), and antianemic preparations (B03) (2.8% vs. 6.7%, RR: 0.4). Higher prevalence was identified for males only for drugs used in diabetes (A10) (6.8% vs. 6.2%, RR: 1.1), particularly for biguanides (A10BA). Conversely, treatment duration was longer among males, explaining the higher mean cost per treated patient. This real-world study showed substantial gender differences in terms of medication use and duration of treatment and costs. These results are relevant to promoting and supporting the emerging role of precision and personalized medicine.

Patterns and predictors of hypothyroid medication use in relation to pregnancy: A drug utilization study

2017 ◽  
Vol 72 ◽  
pp. 208
Author(s):  
Anna S. Frank ◽  
Angela Lupattelli ◽  
Kjetil Røysland ◽  
Hedvig Nordeng
Keyword(s):  
Drug Utilization ◽  
Medication Use ◽  
Drug Utilization Study

scholarly journals Prevalence of medication use among low risk pregnant women: A drug utilization study

2014 ◽  
Vol 8 (36) ◽  
pp. 883-892 ◽  
Author(s):  
Fontoura Andrea ◽  
R. Ayres Lorena ◽  
Martins-Nagai Michelly ◽  
L. S. Dewulf Nathalie ◽  
dos Santos Vania ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Drug Utilization ◽  
Medication Use ◽  
Low Risk ◽  
Drug Utilization Study

A drug utilization study of oral hypoglycemic drugs and insulin in diabetic patients: Face to face with reality

2019 ◽  
Vol 11 (3) ◽  
pp. 25-29
Author(s):  
Suyog S Chopade ◽  
◽  
Rahul P Bhavsar ◽  
Devendra R Chaudhari ◽  
Bapurao M Bite ◽  
...  
Keyword(s):  
Drug Utilization ◽  
Diabetic Patients ◽  
Drug Utilization Study ◽  
Face To Face ◽  
Oral Hypoglycemic Drugs

Fostemsavir

2021 ◽  
pp. 001857872098543
Author(s):  
Brittany M. Craft ◽  
Danial E. Baker
Keyword(s):  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

scholarly journals Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data

2021 ◽  
Vol 18 (9) ◽  
pp. 4754
Author(s):  
Miguel Ángel Hernández-Rodríguez ◽  
Ermengol Sempere-Verdú ◽  
Caterina Vicens-Caldentey ◽  
Francisca González-Rubio ◽  
Félix Miguel-García ◽  
...  
Keyword(s):  
Psychotropic Drugs ◽  
Large Scale ◽  
Anatomical Therapeutic Chemical ◽  
Drug Prescription ◽  
Age Groups ◽  
System Level ◽  
Real World Data ◽  
Converting Enzyme Inhibitors ◽  
Cross Sectional ◽  
Β Blockers

We aimed to identify and compare medication profiles in populations with polypharmacy between 2005 and 2015. We conducted a cross-sectional study using information from the Computerized Database for Pharmacoepidemiologic Studies in Primary Care (BIFAP, Spain). We estimated the prevalence of therapeutic subgroups in all individuals 15 years of age and older with polypharmacy (≥5 drugs during ≥6 months) using the Anatomical Therapeutic Chemical classification system level 4, by sex and age group, for both calendar years. The most prescribed drugs were proton-pump inhibitors (PPIs), statins, antiplatelet agents, benzodiazepine derivatives, and angiotensin-converting enzyme inhibitors. The greatest increases between 2005 and 2015 were observed in PPIs, statins, other antidepressants, and β-blockers, while the prevalence of antiepileptics was almost tripled. We observed increases in psychotropic drugs in women and cardiovascular medications in men. By patient´s age groups, there were notable increases in antipsychotics, antidepressants, and antiepileptics (15–44 years); antidepressants, PPIs, and selective β-blockers (45–64 years); selective β-blockers, biguanides, PPIs, and statins (65–79 years); and in statins, selective β-blockers, and PPIs (80 years and older). Our results revealed important increases in the use of specific therapeutic subgroups, like PPIs, statins, and psychotropic drugs, highlighting opportunities to design and implement strategies to analyze such prescriptions’ appropriateness.

scholarly journals Lixisenatide

2017 ◽  
Vol 52 (1) ◽  
pp. 65-80
Author(s):  
Danial E. Baker ◽  
Terri L. Levien
Keyword(s):  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The January 2017 monograph topics are bezlotoxumab, buprenorphine buccal, defazacort, dupilumab, and olaratumab. The DUE is on buprenorphine buccal.

Sign in / Sign up

Export Citation Format

Share Document